Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials - PubMed
3 months ago
- #statin-therapy
- #adverse-effects
- #meta-analysis
- Meta-analysis of double-blind RCTs assesses adverse effects of statin therapy listed in product labels.
- Only 4 out of 66 adverse effects were statistically significant: abnormal liver transaminases, other liver function test abnormalities, urinary composition alteration, and oedema.
- Findings suggest no causal link between statins and many conditions listed in labels (e.g., cognitive impairment, depression).
- Calls for revision of product labels to reflect evidence from blinded trials for better-informed decisions.
- Study funded by British Heart Foundation, UK Medical Research Council, and Australian National Health and Medical Research Council.